BioSpace News Archive

Policy

Fujifilm Receives Innovative Technology Designation From Vizient for Its Digital Radiography Solutions Including the FDR AQRO and FDR D-EVO GL Panel

The designations were based on direct feedback from hospital clinicians who interacted with the FDR AQRO and FDR D-EVO GL Panel at the Vizient Innovative Technology Exchange in Denver, Colo. on September 14, 2017.

November 9, 2017

·

4 min read

Biotech Beach

AcuFocus Release: KAMRA Corneal Inlay Delivers Uncompromised Vision for Presbyopic Patients

With the KAMRA inlay, you can restore your reading vision while maintaining great distance vision by extending your overall depth of focus.

November 9, 2017

·

4 min read

Oncimmune: Launch of ‘Finger Stick’ Sample Collection for EarlyCDT-Lung

Simplified blood sample collection procedure introduces ease of use and quicker results.

November 9, 2017

·

3 min read

Business

Median Technologies Appoints Dr. Peter Bannister as Chief Technology Officer

As Chief Technology Officer, Dr. Bannister is responsible for leading the development and scientific research teams at Median and ensuring that Median’s products directly address the unmet healthcare needs identified by the company’s clinical end users.

November 9, 2017

·

4 min read

Business

Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results

Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively.

November 9, 2017

·

9 min read

Drug Development

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

These data will be presented at 4:45 P.M. E.T. on Saturday, November 11th.

November 9, 2017

·

8 min read

Business

iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”

Best of ASTRO meeting recognizes most relevant and highly influential research at ASTRO 2017.

November 9, 2017

·

4 min read

Drug Development

Iovance Biotherapeutics Announces New LN-144 Phase II Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting

The data shows that administration of the company’s Generation 2 (Gen 2) manufacturing process in nine efficacy-evaluable metastatic melanoma patients resulted in a disease control rate (DCR) of 78%, which includes 3 confirmed partial responders (PRs) and a fourth PR awaiting confirmation.

November 9, 2017

·

7 min read

Drug Development

TRACON Pharmaceuticals Presents Updated Data from Phase Ib/II Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma

Combination treatment continues to demonstrate encouraging signs of activity.

November 9, 2017

·

5 min read

Drug Development

Vascular Therapies Announces Preliminary Results From its Phase III AV Fistula Study

Vascular Therapies presented preliminary results relating to analysis of the first 18 patients from its US Phase III study.

November 9, 2017

·

3 min read